Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.39 |
| ▸ | CPA1 | P15085 | 2/20 | 0.37 |
| ▸ | GABBR2 | O75899 | 1/20 | 0.37 |
| ▸ | GABBR1 | Q9UBS5 | 1/20 | 0.37 |
| ▸ | CPB1 | P15086 | 1/20 | 0.37 |
| ▸ | CPA3 | P15088 | 1/20 | 0.37 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.37 |
| ▸ | MMP2 | P08253 | 5/20 | 0.36 |
| ▸ | MMP3 | P08254 | 3/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5747649 | 1.00 | MAPT (0.40) | MAPTFFAR1CPA1GABBR2GABBR1 | |
| SCHEMBL5831033 | 1.00 | MAPT (0.40) | MAPTFFAR1CPA1GABBR2GABBR1 | |
| SCHEMBL13014511 | 0.88 | MAPT (0.35) | MAPT | |
| SCHEMBL3778543 | 0.88 | MAPT (0.35) | MAPT | |
| SCHEMBL5830575 | 0.87 | KCNA5 (0.42) | MAPT | |
| SCHEMBL3403997 | 0.87 | KCNA5 (0.42) | MAPT | |
| SCHEMBL3779621 | 0.87 | KCNA5 (0.42) | MAPT | |
| SCHEMBL25175870 | 0.85 | MAPT (0.38) | MAPTFFAR1GABBR2GABBR1MMP2 | |
| SCHEMBL8952823 | 0.85 | MAPT (0.38) | MAPTFFAR1GABBR2GABBR1MMP2 | |
| SCHEMBL8892070 | 0.85 | FFAR1 (0.37) | FFAR1CPA3CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4308570-A1 | MACROCYCLIC LRRK2 KINASE INHIBITORS | Les Laboratoires Servier (FR) | 2024-01-24 | — | — | EP | disclosed |
| CN-117425661-A | Macrocyclic LRRK2 kinase inhibitors | 法国施维雅药厂 | 2024-01-19 | — | — | CN | disclosed |
| US-8778974-B2 | Trisubstituted 1,2,4 triazoles | JANSSEN PHARMACEUTICA NV (BE) | 2014-07-15 | — | — | US | disclosed |
| EP-2257535-B1 | TRISUBSTITUTED 1,2,4-TRIAZOLES AS NICOTINIC ACETYLCHOLINE RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2013-11-06 | — | — | EP | disclosed |
| US-20100324053-A1 | TRISUBSTITUTED 1,2,4 TRIAZOLES | JANSSEN PHARMACEUTICA NV (BE) | 2010-12-23 | — | — | US | disclosed |
| US-7115740-B2 | Pyrimido compounds having antiproliferative activity | HOFFMANN-LA ROCHE INC. (US) | 2006-10-03 | — | — | US | disclosed |
| EP-1315732-B1 | RADICICOL AND MONOCILLIN AND THEIR ANALOGUES AND USES THEREOF | SLOAN KETTERING INST CANCER (US) | 2006-06-07 | — | — | EP | disclosed |
| EP-1615928-A1 | PYRIMIDO COMPOUNDS | F.HOFFMANN-LA ROCHE AG (CH) | 2006-01-18 | — | — | EP | disclosed |
| WO-2004089955-A1 | PYRIMIDO COMPOUNDS | F.HOFFMANN-LA ROCHE AG (CH) | 2004-10-21 | — | — | WO | disclosed |
| US-20040204427-A1 | Pyrimido compounds having antiproliferative activity | CHEN YI (US) | 2004-10-14 | — | — | US | disclosed |
| EP-1315732-A2 | RADICICOL AND MONOCILLIN AND THEIR ANALOGUES AND USES THEREOF | Sloan-Kettering Institute For Cancer Research (US) | 2003-06-04 | — | — | EP | disclosed |
| US-20020091151-A1 | Novel macrocycles and uses thereof | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2002-07-11 | — | — | US | disclosed |
| WO-2002016369-A2 | NOVEL MACROCYCLES AND USES THEREOF | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2002-02-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040204427-A1 | Pyrimido compounds having antiproliferative activity | FGFR3, FGFR1, FGFR4 | MAPT 3675/4885FFAR1 1420/4885CPA1 4255/4885 |
| US-20100324053-A1 | TRISUBSTITUTED 1,2,4 TRIAZOLES | CHRNA1, CHRNA5, CHRNE | MAPT 1891/4885FFAR1 104/4885CPA1 3934/4885 |
| US-20020091151-A1 | Novel macrocycles and uses thereof | ABCE1, DCK, BDKRB1 | MAPT 4289/4885FFAR1 3521/4885CPA1 2837/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.